TRQ 1201
Alternative Names: Deep Il-12 Primed T cell; Deep™ IL-12; Surface-tethered IL-12 - Torque Therapeutics; TRQ-1201Latest Information Update: 28 May 2022
At a glance
- Originator Torque Therapeutics
- Class Antineoplastics; Cytokines; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants; Interleukin-12 expression stimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 28 May 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 08 Nov 2019 Pharmacodynamics data from preclinical trial released by Torque Therapeutics